Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia

Next Previous
X
Search
Trial Profile

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crinecerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CAHlibrate
  • Sponsors Neurocrine Biosciences

    • Most Recent Events

    • 12 May 2023 Results of post-hoc analysis assessing baseline hormone levels and glucocorticoid (GC) doses correlated with treatment response will be presented at ECE 2023, the 25th European Congress of Endocrinology in Istanbul, Turkey from May 13-16.
    • 12 May 2023 Results presented in a Neurocrine Biosciences Media Release.
    • 15 Oct 2021 Results assessing safety, tolerability, and efficacy of crinecerfont published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top